Literature DB >> 22746051

[Refractory AIDS-associated Kaposi's sarcoma treated successfully with paclitaxel: a case report].

Hirofumi Kato1, Naoki Yanagisawa, Shugo Sasaki, Tomohiro Hosoda, Akihiko Suganuma, Akifumi Imamura, Atsushi Ajisawa.   

Abstract

We report a case of a 45-year-old Japanese man with AIDS-associated Kaposi's sarcoma (KS) involving skin, liver, and lungs. Antiretroviral therapy was started in conjunction with pegylated liposomal doxorubicin (PLD). A clinical response was observed initially, but symptoms recurred following cessation of medication. The chemotherapeutic agent was changed to paclitaxel (PTX), since the therapeutic response to PLD was reduced and the total dose reached the maximum dose of 500 mg/m2. The patient had a good response to PTX and tolerated the medication well. Symptoms did not recur after completing 8 courses of chemotherapy. PTX should be considered as an alternative agent in treating KS when there are problems with the use of PLD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22746051     DOI: 10.11150/kansenshogakuzasshi.86.287

Source DB:  PubMed          Journal:  Kansenshogaku Zasshi        ISSN: 0387-5911


  1 in total

1.  Silencing MAP3K1 expression through RNA interference enhances paclitaxel-induced cell cycle arrest in human breast cancer cells.

Authors:  Pinghua Hu; Qin Huang; Zhihua Li; Xiaobo Wu; Qianwen Ouyang; Jun Chen; Yali Cao
Journal:  Mol Biol Rep       Date:  2013-11-21       Impact factor: 2.316

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.